Analysts fell to the sidelines weighing in on Global Blood Therapeutics (GBT – Research Report) and Cerevel Therapeutics Holdings (CERE – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Global Blood Therapeutics (GBT)
In a report released today, Andreas Argyrides from Wedbush downgraded Global Blood Therapeutics to Hold, with a price target of $68.50. The company’s shares closed last Monday at $66.67, close to its 52-week high of $73.02.
According to TipRanks.com, Argyrides is a 2-star analyst with an average return of
Global Blood Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $60.50, representing a -9.3% downside. In a report released today, Jefferies also downgraded the stock to Hold with a $68.50 price target.
See the top stocks recommended by analysts >>
Cerevel Therapeutics Holdings (CERE)
In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Cerevel Therapeutics Holdings, with a price target of $27.00. The company’s shares closed last Monday at $34.54.
According to TipRanks.com, Suvannavejh is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cerevel Therapeutics Holdings with a $38.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GBT:
- Meritage Announces Third Quarter Common Stock Dividend and Increased Repurchase Authorization
- Transaction in Own Shares
- Avalara (AVLR) was downgraded to a Hold Rating at Needham
- KVH Industries to Host Second Quarter Conference Call on August 9, 2022
- Avast’s stock skyrockets as merger with NortonLifeLock gets green light